دورية أكاديمية
[New targets and new drugs in thoracic oncology].
| العنوان: | [New targets and new drugs in thoracic oncology]. |
|---|---|
| عنوان ترانسليتريتد: | Nouvelles cibles et nouvelles molécules en oncologie thoracique. |
| المؤلفون: | Rouviere D; Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France., Bousquet E; Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France., Pons E; Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France; Service d'oncologie médicale, institut Claudius-Regaud, 31000 Toulouse, France., Milia JD; Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France., Guibert N; Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France., Mazieres J; Service de pneumologie, hôpital Larrey, CHU de Toulouse, université Paul-Sabatier, 31000 Toulouse, France. Electronic address: mazieres.j@chu-toulouse.fr. |
| المصدر: | Revue des maladies respiratoires [Rev Mal Respir] 2015 Oct; Vol. 32 (8), pp. 867-76. Date of Electronic Publication: 2015 Jun 12. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | French |
| بيانات الدورية: | Publisher: Elsevier-Masson Country of Publication: France NLM ID: 8408032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-2588 (Electronic) Linking ISSN: 07618425 NLM ISO Abbreviation: Rev Mal Respir Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2009- > : Issy-les-Moulineaux Cedex, France : Elsevier-Masson Original Publication: Paris ; New York : Masson, c1984- |
| مواضيع طبية MeSH: | Molecular Targeted Therapy*, Drugs, Investigational/*therapeutic use , Lung Neoplasms/*drug therapy , Neoplasm Proteins/*antagonists & inhibitors, Antibodies, Monoclonal/therapeutic use ; Clinical Trials as Topic ; Drugs, Investigational/pharmacology ; Genes, erbB-2 ; Humans ; Lung Neoplasms/genetics ; Mutation ; Neoplasm Proteins/genetics ; Neoplasm Proteins/physiology ; Oncogene Proteins, Fusion/antagonists & inhibitors ; Oncogene Proteins, Fusion/genetics ; Oncogenes ; Phosphatidylinositol 3-Kinases/physiology ; Phosphoinositide-3 Kinase Inhibitors ; Protein Kinase Inhibitors/therapeutic use ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Protein-Tyrosine Kinases/genetics ; Proto-Oncogene Proteins/antagonists & inhibitors ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/physiology ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/physiology ; Signal Transduction/drug effects |
| مستخلص: | A number of mechanisms that drive oncogenesis have been deciphered over the last 20 years. The main oncogenic factors in the field of thoracic oncology are mutations of EGFR, KRAS, and EML4-ALK translocation, which are most often reported in adenocarcinomas. However, new molecular targets have been highlighted recently including BRAF mutations, HER2 or PI3K, new translocations such as ROS1 or KIF5B-RET. Molecular abnormalities have also been identified in tumors other than adenocarcinoma (squamous and small cell carcinoma). Therapeutic strategies have been designed to inhibit these signaling pathways including monoclonal antibodies and tyrosine kinase inhibitors. Some of these molecules are now approved as therapies, others are currently undergoing testing in clinical trials. We here present a review of novel targeted agents for lung cancer. (Copyright © 2015 SPLF. Published by Elsevier Masson SAS. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Biomarkers; Biomarqueurs; Cancer bronchique; Lung cancer; Targeted therapy; Thérapies ciblées |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Drugs, Investigational) 0 (KIF5B-RET fusion protein, human) 0 (Neoplasm Proteins) 0 (Oncogene Proteins, Fusion) 0 (Phosphoinositide-3 Kinase Inhibitors) 0 (Protein Kinase Inhibitors) 0 (Proto-Oncogene Proteins) EC 2.7.10.1 (ERBB2 protein, human) EC 2.7.10.1 (Protein-Tyrosine Kinases) EC 2.7.10.1 (ROS1 protein, human) EC 2.7.10.1 (Receptor, ErbB-2) EC 2.7.11.1 (BRAF protein, human) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) |
| تواريخ الأحداث: | Date Created: 20150617 Date Completed: 20160830 Latest Revision: 20191210 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.rmr.2015.02.091 |
| PMID: | 26076869 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1776-2588 |
|---|---|
| DOI: | 10.1016/j.rmr.2015.02.091 |